Alkermes Cash Flow Statement
NASDAQ: ALKSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alkermes free cash flow
In fiscal 2025, Alkermes generated $520.8 million of operating cash flow and spent $40.4 million on capital expenditures. That left free cash flow of $480.3 million, a free-cash-flow margin of 32.5% of revenue. Free cash flow was up 18.4% from the prior year's $405.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
Alkermes cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 241.66M | 367.07M | 355.76M | -158.27M | -48.17M | -110.86M | -196.62M | -139.31M | -157.94M | -208.44M |
| Net Income growth (YoY) | -34.16% | +3.18% | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 27.16M | 28.53M | 74.93M | 77.86M | 78.65M | 81.85M | 80.41M | 103.66M | 98.52M | 94.26M |
| Stock-Based Compensation | 98.72M | 96.64M | 100.91M | 94.25M | 87.62M | 90.16M | 100.98M | 105.36M | 83.92M | 94.40M |
| Change in Working Capital | 141.38M | -102.02M | -20.80M | 15.36M | -61.68M | -50.91M | 73.06M | -2.31M | 4.63M | -12.19M |
| Operating Cash Flow | 520.75M | 439.12M | 401.35M | 21.04M | 101.72M | 82.84M | 72.08M | 99.28M | 19.19M | -63.80M |
| Capital Expenditures | -40.42M | -33.48M | -48.05M | -38.26M | -28.02M | -42.22M | -90.94M | -69.43M | -51.30M | -43.66M |
| Investing Cash Flow | 295.50M | -111.31M | 53.36M | -64.54M | -66.20M | -11.48M | -141.83M | -22.20M | -18.36M | 127.24M |
| Share Repurchases | — | -200.28M | — | — | — | — | — | — | — | — |
| Debt Issued | — | — | — | — | 23.57M | — | — | — | — | — |
| Debt Repaid | — | -2.25M | -3.00M | -3.00M | -2.25M | -2.84M | -2.84M | -743.00K | -3.00M | -3.43M |
| Financing Cash Flow | 12.38M | -494.14M | -289.71M | -1.57M | 29.07M | -2.17M | 6.76M | -1.62M | 4.08M | -58.17M |
| Net Change in Cash | 828.63M | -166.32M | 165.00M | -45.07M | 64.58M | 69.19M | -62.99M | 75.47M | 4.92M | 5.27M |
| Free Cash Flow | 480.33M | 405.64M | 353.31M | -17.21M | 73.69M | 40.62M | -18.86M | 29.85M | -32.11M | -107.46M |
This table shows 10 annual periods of Alkermes's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ALKS's reporting calendar. What is a cash flow statement?